{"id":31143,"date":"2025-04-02T16:50:27","date_gmt":"2025-04-02T08:50:27","guid":{"rendered":"https:\/\/flcube.com\/?p=31143"},"modified":"2025-04-02T16:50:29","modified_gmt":"2025-04-02T08:50:29","slug":"organon-acquires-u-s-rights-to-tofidence-from-biogen","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31143","title":{"rendered":"Organon Acquires U.S. Rights to TOFIDENCE from Biogen"},"content":{"rendered":"\n

Organon (NYSE: OGN<\/a>) announced today that it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE, a biosimilar to ACTEMRA, from Biogen Inc. (NASDAQ: BIIB<\/a>). This acquisition follows an agreement where Bio-Thera Solutions Ltd., the developer of TOFIDENCE, granted Biogen exclusive rights to the product in global markets excluding China in April 2021.<\/p>\n\n\n\n

Agreement Details<\/strong>
Under the terms of the agreement, Organon has obtained regulatory and commercial rights to TOFIDENCE in the U.S., while Bio-Thera will retain manufacturing rights for the U.S. market. The deal includes an upfront payment to Biogen, with Organon assuming the obligation to pay tiered royalty payments based on net sales and tiered annual net sales milestone payments owed by Biogen to Bio-Thera.<\/p>\n\n\n\n

Product Profile<\/strong>
TOFIDENCE, the first approved tocilizumab biosimilar in the U.S. market, was launched in May 2024. It is indicated for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Organon (NYSE: OGN) announced today that it has acquired regulatory and commercial rights in the…<\/p>\n","protected":false},"author":1,"featured_media":31144,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[351,43,993,972,174],"class_list":["post-31143","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biogen","tag-biosimilars","tag-nasdaq-biib","tag-nyse-ogn","tag-organon"],"yoast_head":"\nOrganon Acquires U.S. Rights to TOFIDENCE from Biogen - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Organon (NYSE: OGN) announced today that it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE, a biosimilar to ACTEMRA, from Biogen Inc. (NASDAQ: BIIB). This acquisition follows an agreement where Bio-Thera Solutions Ltd., the developer of TOFIDENCE, granted Biogen exclusive rights to the product in global markets excluding China in April 2021.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31143\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Organon Acquires U.S. Rights to TOFIDENCE from Biogen\" \/>\n<meta property=\"og:description\" content=\"Organon (NYSE: OGN) announced today that it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE, a biosimilar to ACTEMRA, from Biogen Inc. (NASDAQ: BIIB). This acquisition follows an agreement where Bio-Thera Solutions Ltd., the developer of TOFIDENCE, granted Biogen exclusive rights to the product in global markets excluding China in April 2021.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31143\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-02T08:50:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-02T08:50:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0208-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31143#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31143\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Organon Acquires U.S. Rights to TOFIDENCE from Biogen\",\"datePublished\":\"2025-04-02T08:50:27+00:00\",\"dateModified\":\"2025-04-02T08:50:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31143\"},\"wordCount\":177,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31143#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0208-png.webp\",\"keywords\":[\"Biogen\",\"Biosimilars\",\"NASDAQ: BIIB\",\"NYSE: OGN\",\"Organon\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31143#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31143\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31143\",\"name\":\"Organon Acquires U.S. Rights to TOFIDENCE from Biogen - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31143#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31143#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0208-png.webp\",\"datePublished\":\"2025-04-02T08:50:27+00:00\",\"dateModified\":\"2025-04-02T08:50:29+00:00\",\"description\":\"Organon (NYSE: OGN) announced today that it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE, a biosimilar to ACTEMRA, from Biogen Inc. (NASDAQ: BIIB). This acquisition follows an agreement where Bio-Thera Solutions Ltd., the developer of TOFIDENCE, granted Biogen exclusive rights to the product in global markets excluding China in April 2021.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31143#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31143\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31143#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0208-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0208-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Organon Acquires U.S. Rights to TOFIDENCE from Biogen\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31143#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Organon Acquires U.S. Rights to TOFIDENCE from Biogen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Organon Acquires U.S. Rights to TOFIDENCE from Biogen - Insight, China's Pharmaceutical Industry","description":"Organon (NYSE: OGN) announced today that it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE, a biosimilar to ACTEMRA, from Biogen Inc. (NASDAQ: BIIB). This acquisition follows an agreement where Bio-Thera Solutions Ltd., the developer of TOFIDENCE, granted Biogen exclusive rights to the product in global markets excluding China in April 2021.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31143","og_locale":"en_US","og_type":"article","og_title":"Organon Acquires U.S. Rights to TOFIDENCE from Biogen","og_description":"Organon (NYSE: OGN) announced today that it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE, a biosimilar to ACTEMRA, from Biogen Inc. (NASDAQ: BIIB). This acquisition follows an agreement where Bio-Thera Solutions Ltd., the developer of TOFIDENCE, granted Biogen exclusive rights to the product in global markets excluding China in April 2021.","og_url":"https:\/\/flcube.com\/?p=31143","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-02T08:50:27+00:00","article_modified_time":"2025-04-02T08:50:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0208-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31143#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31143"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Organon Acquires U.S. Rights to TOFIDENCE from Biogen","datePublished":"2025-04-02T08:50:27+00:00","dateModified":"2025-04-02T08:50:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31143"},"wordCount":177,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31143#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0208-png.webp","keywords":["Biogen","Biosimilars","NASDAQ: BIIB","NYSE: OGN","Organon"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31143#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31143","url":"https:\/\/flcube.com\/?p=31143","name":"Organon Acquires U.S. Rights to TOFIDENCE from Biogen - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31143#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31143#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0208-png.webp","datePublished":"2025-04-02T08:50:27+00:00","dateModified":"2025-04-02T08:50:29+00:00","description":"Organon (NYSE: OGN) announced today that it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE, a biosimilar to ACTEMRA, from Biogen Inc. (NASDAQ: BIIB). This acquisition follows an agreement where Bio-Thera Solutions Ltd., the developer of TOFIDENCE, granted Biogen exclusive rights to the product in global markets excluding China in April 2021.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31143#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31143"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31143#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0208-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0208-png.webp","width":1080,"height":608,"caption":"Organon Acquires U.S. Rights to TOFIDENCE from Biogen"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31143#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Organon Acquires U.S. Rights to TOFIDENCE from Biogen"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0208-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31143"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31143\/revisions"}],"predecessor-version":[{"id":31145,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31143\/revisions\/31145"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31144"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}